Reata Pharmaceuticals announced plans to initiate a study using the drug bardoxolone methyl in the treatment of chronic kidney disease caused by Alport Syndrome. The clinical trial (CARDINAL) will study how bardoxolone methyl affects the chronic inflammation and decline in kidney function that are key features of Alport Syndrome.
Regulus Therapeutics is pleased to announce the initiation of the HERA study, an interventional clinical study in Alport syndrome patients. The purpose of this research study is to evaluate the safety and effectiveness of an investigational drug (an anti-microRNA 21 called RG-012) compared to placebo as a treatment for patients with Alport syndrome.
Registries are an important part of moving research in Alport syndrome forward. Dr. Michelle Rheault, the Co‐Director of the University of Minnesota’s Alport Syndrome Treatment and Outcomes Registry (ASTOR) explains how registries work and why you should consider enrolling.
I used to think that as a patient I had no power to effect change for my family and others with Alport Syndrome – that we had to endure the recurring cycle of disease, generation after generation. I now know that we, as patients, play a pivotal role in changing the course of the disease and our actions will have a tremendous impact on our future.